Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ39T6)

• Drug Name: AVID200 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMZ39T6

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[3]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[4]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[3]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[5]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[6]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[9]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03834662) A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies. U.S. National Institutes of Health.
• [2] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [5] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [6] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [7] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Agenus.
• [9] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [10] Clinical pipeline report, company report or official report of Roche